SPIN-CHAT多组分教育支持项目对系统性硬化症患者焦虑症状的影响:一项随机对照试验
该试验评估SPIN-CHAT项目对系统性硬化症患者焦虑症状的影响,将172名有轻度焦虑的参与者随机分入干预组或等待组。干预后焦虑症状未显著改善,但6周后焦虑和抑郁症状显著降低,未报告不良事件。
要点
- 干预后焦虑症状未显著降低,但6周后焦虑和抑郁症状显著改善。
- 干预为4周视频会议小组形式,提供教育、应对策略练习和社会支持。
- 研究未报告不良事件,提示干预安全性良好。
核心结论
- SPIN-CHAT干预未显著改善干预后焦虑症状或其他心理健康结局,但6周后焦虑和抑郁症状显著降低。
- 多组分干预如SPIN-CHAT有潜力应对COVID-19期间脆弱群体的心理健康需求,但有效性仍不确定。
研究设计与样本
- 实用、两臂、平行、部分嵌套的随机对照试验,1:1分配至干预组或等待组。
- 从国际SPIN COVID-19队列招募系统性硬化症患者,纳入标准包括完成基线测量、至少轻度焦虑症状、未检测COVID-19阳性且未接受心理咨询。
主要发现
- 未报告不良事件。
关键数值与推荐
- 主要结局为干预后立即评估的焦虑症状(PROMIS Anxiety 4a version 1.0)。
- 干预为4周(每周3次)视频会议小组干预,提供心理健康应对策略的教育和实践,以及社会支持,每组6-10名参与者。
临床怎么用
- 对于系统性硬化症合并轻度焦虑的患者,可考虑提供类似SPIN-CHAT的多组分教育支持干预,但需注意焦虑改善可能延迟至6周。
- 干预未显示短期(干预后)焦虑改善,临床决策时应结合患者具体情况和可用资源。
局限性
- 干预后主要结局未显著改善,6周后改善可能反映延迟效应,但不确定性仍存在。
- 样本以女性、白人为主,结果外推需谨慎。
- 试验在COVID-19期间进行,特定背景可能影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No trials have tested multifaceted mental health interventions recommended by public health organisations during COVID-19. The objective of this trial was to evaluate the effect of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program on anxiety symptoms and other mental health outcomes among people vulnerable during COVID-19 owing to a pre-existing medical condition. METHODS: The SPIN-CHAT Trial was a pragmatic, two-arm, parallel, partially nested, randomised, controlled trial (1:1 allocation to intervention or waitlist). Eligible participants with systemic sclerosis were recruited from the international SPIN COVID-19 Cohort. SPIN COVID-19 Cohort participants were eligible for the trial if they completed baseline measures and had at least mild anxiety symptoms, had not tested positive for COVID-19, and were not currently receiving mental health counselling. SPIN-CHAT is a 4-week (3 sessions per week) videoconference-based group intervention that provided education and practice with mental health coping strategies, and provided social support to reduce isolation. Groups included 6-10 participants. The primary outcome analysed in the intention-to-treat population was anxiety symptoms (PROMIS Anxiety 4a version 1.0) immediately post-intervention. This trial is registered with ClinicalTrials.gov, NCT04335279 and is complete. FINDINGS: Of participants who completed baseline measures between April 9, 2020, and April 27, 2020, 560 participants were eligible and 172 participants were randomly assigned to intervention (n=86) or waitlist (n=86). Mean age was 55·0 years (SD 11·4 years), 162 (94%) were women, and 136 (79%) identified as White. In intention-to-treat analyses, the intervention did not significantly reduce anxiety symptoms post-intervention (-1·57 points, 95% CI -3·59 to 0·45; standardised mean difference [SMD] -0·22 points) but reduced symptoms 6 weeks later (-2·36 points, 95% CI -4·56 to -0·16; SMD -0·31). Depression symptoms were significantly lower 6 weeks post-intervention (-1·64 points, 95% CI -2·91 to -0·37; SMD -0·31); no other secondary outcomes were significant. No adverse events were reported. INTERPRETATION: The intervention did not significantly improve anxiety symptoms or other mental health outcomes post-intervention. However, anxiety and depression symptoms were significantly lower 6 weeks later, potentially capturing the time it took for new skills and social support between intervention participants to affect mental health. Multi-faceted interventions such as SPIN-CHAT have potential to address mental health needs in vulnerable groups during COVID-19, yet uncertainty remains about effectiveness. FUNDING: Canadian Institutes of Health Research (CIHR; VR4-172745, MS1-173066); McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund; Scleroderma Canada, made possible by an educational grant for patient support programming from Boehringer Ingelheim; the Scleroderma Society of Ontario; Scleroderma Manitoba; Scleroderma Atlantic; Scleroderma Australia; Scleroderma New South Wales; Scleroderma Victoria; Scleroderma Queensland; Scleroderma SASK; the Scleroderma Association of BC; and Sclérodermie Québec.
引用
- Thombs BD, Kwakkenbos L, Levis B, et al. Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial. Lancet Rheumatol. 2021. PMID: 33899008. doi:10.1016/S2665-9913(21)00060-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。